Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol for Severe Acute GVHD
NCT02392780Phase 2Unknown
- Start
- Apr 2015
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cannabidiol in Acute Graft-Versus-Host Disease (aGvHD). Primary endpoint: Proportion of patients with complete remission of acute GVHD at 90 days. Status: unknown.
02
Drugs
cannabidiol
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT02392780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02392780.